GO:0015747 urate transport: Renal Urate Handling, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015747 urate transport describes the directed movement of urate (uric acid) into, out of, or between cells via transporters or pores.
• Urate transport is essential for maintaining serum urate homeostasis, and its dysregulation is central to hyperuricemia and gout [1, 4].
• Key transporters include URAT1 (SLC22A12), GLUT9 (SLC2A9), OAT1/3 (SLC22A6/8), ABCG2, and others that mediate reabsorption and secretion in the kidney and intestine [1, 2, 6].
• Both transcellular and paracellular routes contribute to renal urate handling, with the proximal tubule playing a dominant role [3, 5, 8].
• Genetic variants in urate transporters are associated with gout, kidney stones, and cardiovascular/metabolic traits [1, 4].
• CRISPR-based models (knockout, knock-in, point mutation) are powerful tools to dissect the causal roles of urate transport genes in disease [1, 2].
Description
Urate transport (GO:0015747) is the biological process by which urate, the end product of purine metabolism in humans, is moved across cell membranes or between cells via specific transporters or pores. This process is critical for maintaining systemic urate balance, as humans lack the enzyme uricase and rely on efficient renal and intestinal excretion to prevent urate accumulation. Dysregulation of urate transport leads to hyperuricemia, a prerequisite for gout and a risk factor for kidney and cardiovascular diseases [1, 4]. Research into urate transport has revealed a complex interplay of multiple transporters with distinct roles in reabsorption and secretion, primarily in the renal proximal tubule and intestine [3, 6]. Understanding these mechanisms is essential for developing targeted therapies for hyperuricemia and gout, and for elucidating the broader metabolic roles of urate [1, 2].
urate transport At A Glance
| GO ID | GO:0015747 |
|---|---|
| GO term | urate transport |
| Ontology | biological_process |
| Synonym | urate transmembrane transport; uric acid transport |
| Major function | Mediates the movement of urate across cell membranes and between cells, maintaining urate homeostasis. |
| Cellular location | Plasma membrane of epithelial cells, particularly in renal proximal tubule and intestine. |
| Key transporters | URAT1 (SLC22A12), GLUT9 (SLC2A9), OAT1/3 (SLC22A6/8), ABCG2, and others. |
| Physiological relevance | Regulates serum urate levels; dysfunction causes hyperuricemia and gout. |
| Research impact | Target for urate-lowering therapies and genetic studies of gout and metabolic disorders. |
What Is GO:0015747?
According to the Gene Ontology, GO:0015747 urate transport is defined as the directed movement of urate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. It encompasses the translocation of urate across biological membranes, including transmembrane transport and transport between cells, and is synonymous with urate transmembrane transport and uric acid transport.
Why Is urate transport Important in Cell Biology?
Urate transport is fundamental to human health because it determines serum urate concentrations, and its dysregulation is directly linked to hyperuricemia, gout, and associated comorbidities such as hypertension, chronic kidney disease, and cardiovascular disorders [1, 4]. The process is also a major determinant of drug pharmacokinetics, as many uricosuric and anti-gout drugs target urate transporters [2, 6]. Moreover, urate transport influences antioxidant defense and immune responses, highlighting its broader biological significance.
• Maintains serum urate homeostasis; defects cause hyperuricemia and gout [1, 4].
• Renal urate handling is a key determinant of urate excretion and is targeted by uricosuric drugs [2, 6].
• Genetic variants in urate transporters are associated with gout, kidney stones, and metabolic syndrome [1, 4].
• Intestinal urate excretion contributes significantly to overall urate balance, especially in chronic kidney disease.
• Urate transport modulates intracellular urate levels, affecting oxidative stress and inflammasome activation.
• Provides a model for studying epithelial transport and membrane protein structure-function [2, 5].
• Relevant to drug development: inhibitors of URAT1 (e.g., lesinurad, benzbromarone) are used clinically.
• Paracellular urate transport is an emerging area with implications for epithelial barrier function.
• Comparative studies reveal evolutionary adaptations in urate handling among species.
• Experimental models (knockout mice, cell lines) are essential for causal inference [1, 2].
What Happens During urate transport?
Urate uptake at the basolateral membrane
In simple terms: Urate enters proximal tubule cells from the blood through specific transporters on the basolateral side.
In the renal proximal tubule, urate is taken up from the peritubular capillaries across the basolateral membrane primarily via OAT1 (SLC22A6) and OAT3 (SLC22A8), which are organic anion transporters that exchange urate with dicarboxylates [3, 6]. This step is the first in a series of transport events that ultimately lead to urate secretion or reabsorption. The driving force is provided by the sodium gradient and intracellular dicarboxylate concentrations.
Intracellular urate handling and transport to the apical membrane
In simple terms: Inside the cell, urate is moved toward the apical membrane for secretion or reabsorption.
Once inside the cell, urate can be transported to the apical membrane by mechanisms that are not fully understood but may involve vesicular transport or binding to intracellular proteins. The apical membrane transporters URAT1 (SLC22A12) and GLUT9 (SLC2A9) play key roles in urate reabsorption from the tubular lumen into the cell, while ABCG2 and others mediate secretion into the lumen [1, 2]. The interplay between these transporters determines the net direction of urate transport.
Apical urate reabsorption and secretion
In simple terms: At the apical membrane, urate is either reabsorbed into the cell or secreted into the urine.
URAT1 (SLC22A12) is a major apical transporter that reabsorbs urate from the tubular lumen in exchange for organic anions, while GLUT9 (SLC2A9) facilitates urate efflux across the basolateral membrane [1, 2]. ABCG2, an ATP-binding cassette transporter, mediates urate secretion into the urine and intestine. The balance between reabsorption and secretion determines final urate excretion.
Paracellular urate transport
In simple terms: Urate can also leak between cells through the paracellular pathway.
In addition to transcellular transport, urate can move across epithelial cells via the paracellular route, driven by electrochemical gradients and solvent drag. This route may contribute significantly to urate transport under certain conditions, such as in the intestine or when transcellular transporters are saturated. The tight junction proteins that regulate paracellular permeability are potential modulators of urate transport.
Intestinal urate transport
In simple terms: The intestine also transports urate, contributing to overall urate elimination.
The intestine expresses several urate transporters, including ABCG2 and GLUT9, which mediate urate secretion into the gut lumen for excretion. Intestinal urate transport becomes particularly important in chronic kidney disease, where renal excretion is impaired. This extrarenal pathway is a target for therapeutic intervention.
Key Genes Involved in GO:0015747 urate transport
The following genes encode transporters and related proteins that mediate urate transport (GO:0015747) across cell membranes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC22A12 (URAT1) | Apical urate reabsorption in renal proximal tubule | Major target for uricosuric drugs; loss-of-function causes renal hypouricemia [1, 2] |
| SLC2A9 (GLUT9) | Basolateral urate efflux; also in intestine | Genetic variants associated with gout and serum urate levels [1, 2] |
| SLC22A6 (OAT1) | Basolateral urate uptake in kidney | Mediates secretion; drug interactions [3, 6] |
| SLC22A8 (OAT3) | Basolateral urate uptake in kidney | Contributes to urate secretion; drug interactions [3, 6] |
| ABCG2 (BCRP) | Apical urate secretion in kidney and intestine | Gout risk gene; mediates intestinal urate excretion |
| SLC17A1 (NPT1) | Apical urate transport in kidney | Associated with gout in GWAS |
| SLC17A3 (NPT4) | Apical urate transport in kidney | Voltage-driven urate efflux; gout susceptibility |
| SLC22A11 (OAT4) | Apical urate reabsorption | Urate transport in exchange for organic anions |
| SLC22A13 (OAT10) | Apical urate reabsorption | Contributes to urate reabsorption |
| PDZK1 | Scaffolding protein for urate transporters | Regulates URAT1 and other transporters |
| SLC26A6 | Apical oxalate/urate exchanger | May influence urate transport indirectly |
| SLC13A3 (NaDC3) | Basolateral dicarboxylate transporter | Provides driving force for OAT-mediated urate uptake |
| SLC5A8 (SMCT1) | Apical monocarboxylate transporter | May affect urate reabsorption via organic anion exchange |
| SLC16A9 (MCT9) | Urate transport in kidney | GWAS association with urate levels |
| SLC22A9 (OAT7) | Urate transport in liver | Hepatic urate handling |
| SLC22A2 (OCT2) | Organic cation transporter | May transport urate in some tissues |
| SLC22A4 (OCTN1) | Organic cation/carnitine transporter | Urate transport in kidney and intestine |
| SLC22A5 (OCTN2) | Organic cation/carnitine transporter | Urate transport in kidney and intestine |
How Is urate transport Regulated?
Urate transport is regulated at multiple levels. Transcriptional regulation of transporters such as URAT1 and GLUT9 by hormones (e.g., insulin, angiotensin II) and metabolic factors modulates urate reabsorption. Post-translational modifications, including phosphorylation and ubiquitination, affect transporter trafficking and activity. PDZK1 acts as a scaffold to assemble transporter complexes at the apical membrane. Additionally, urate itself can regulate transporter expression via feedback mechanisms. In disease states, inflammatory cytokines and oxidative stress can alter urate transport capacity.
urate transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC22A12 (URAT1) | Renal hypouricemia, gout | Knockout mouse, HEK293 overexpression, point mutation (e.g., W258X) |
| SLC2A9 (GLUT9) | Gout, hyperuricemia, renal hypouricemia | Liver-specific knockout, knock-in of common variants (e.g., rs16890979) |
| ABCG2 | Gout, hyperuricemia, intestinal urate excretion | Intestinal epithelial knockout, Q141K knock-in |
| SLC22A6 (OAT1) | Drug-induced hyperuricemia, CKD | Knockout mouse, transporter-overexpressing cell lines |
| SLC22A8 (OAT3) | Gout, drug interactions | Knockout mouse, competitive transport assays |
Hyperuricemia and Gout
Hyperuricemia, defined as elevated serum urate, is the primary risk factor for gout. It arises from overproduction or underexcretion of urate, with underexcretion accounting for the majority of cases [1, 4]. Genetic variants in urate transporters, particularly URAT1 (SLC22A12), GLUT9 (SLC2A9), and ABCG2, are strongly associated with gout risk. Loss-of-function mutations in URAT1 cause renal hypouricemia, while gain-of-function variants may increase reabsorption and predispose to hyperuricemia. Uricosuric drugs such as probenecid and lesinurad target URAT1 to increase urate excretion.
Chronic Kidney Disease and Cardiovascular Disease
Impaired renal urate transport contributes to hyperuricemia in chronic kidney disease (CKD), and elevated urate is an independent risk factor for CKD progression and cardiovascular events [1, 4]. Urate transport in the intestine becomes a compensatory pathway in CKD, and targeting intestinal ABCG2 may offer therapeutic benefit. The interplay between urate transport and oxidative stress, inflammation, and endothelial dysfunction underlies the association with cardiovascular disease.
Kidney Stones and Metabolic Syndrome
Altered urate transport can lead to hyperuricosuria, promoting uric acid kidney stone formation. Additionally, urate transport genes have been linked to metabolic syndrome traits, including hypertension, insulin resistance, and obesity, in genome-wide association studies [1, 4]. The mechanistic links may involve intracellular urate effects on adipocytes and pancreatic beta cells.
From urate transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of URAT1 affect serum urate and renal excretion? | SLC22A12 knockout mouse or HEK293 knockout cells |
| What is the effect of a gout-associated ABCG2 variant on urate transport? | ABCG2 Q141K knock-in mouse or overexpression in polarized cells |
| Can a candidate transporter mediate urate transport? | Overexpression in Xenopus oocytes or HEK293 cells followed by radiolabeled urate uptake |
| How does PDZK1 regulate URAT1 trafficking? | PDZK1 knockout mouse, tagged knock-in of URAT1 |
| What is the role of intestinal urate transport in CKD? | Intestine-specific ABCG2 knockout mouse |
| Does a point mutation in SLC2A9 alter urate efflux? | Site-directed mutagenesis and knock-in of mutant GLUT9 in cell lines |
How to Study the urate transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled urate uptake | Transport activity and kinetics | Characterization of candidate transporters in cell lines |
| Knockout mouse models | Physiological role of transporter in urate homeostasis | Renal urate excretion studies |
| GWAS | Genetic associations with serum urate and gout | Identification of urate transport loci |
| Cryo-EM | Three-dimensional structure of transporters | Structure-guided drug design |
| RNA-seq | Expression levels of urate transporters | Tissue-specific expression profiling |
| CRISPR screens | Identification of genes regulating urate transport | Discovery of novel modulators |
| Site-directed mutagenesis | Function of specific amino acid residues | Mapping of substrate binding site |
| Paracellular flux assays | Paracellular transport contribution | Epithelial barrier studies |
Transport Assays
Radiolabeled urate uptake assays in cell lines or Xenopus oocytes expressing candidate transporters are the gold standard for measuring transport activity [2, 6]. These assays can determine kinetics (Km, Vmax), substrate specificity, and inhibitor sensitivity. For example, URAT1-mediated urate transport is typically measured in HEK293 cells transfected with SLC22A12.
Genetically Modified Models
Knockout and transgenic mouse models are essential for studying the physiological role of urate transporters in vivo. Tissue-specific knockouts (e.g., intestinal ABCG2) can dissect the contribution of specific organs. Knock-in models of human gout-associated variants (e.g., ABCG2 Q141K) provide insights into disease mechanisms.
Genomic and Transcriptomic Approaches
Genome-wide association studies (GWAS) have identified numerous loci associated with serum urate and gout, many of which harbor urate transporter genes. RNA-seq and single-cell transcriptomics can reveal tissue-specific expression patterns of transporters. CRISPR screens can identify novel regulators of urate transport.
Structural and Biophysical Methods
Cryo-EM and X-ray crystallography have provided structures of URAT1 and other transporters, revealing the binding pocket and transport mechanism. These structures guide the design of novel inhibitors. Molecular dynamics simulations complement structural studies to understand conformational changes during transport.
How CRISPR Can Be Used to Study GO:0015747 urate transport
Knockout
CRISPR knockout of urate transporter genes (e.g., SLC22A12, SLC2A9, ABCG2) in cell lines or mice abolishes specific transport activities, allowing researchers to attribute urate flux to individual transporters [1, 2]. For example, knockout of URAT1 in HEK293 cells eliminates urate uptake, confirming its role as a reabsorptive transporter.
Point Mutation
Introducing disease-associated point mutations (e.g., ABCG2 Q141K, URAT1 W258X) via CRISPR base editing or homology-directed repair recapitulates human phenotypes in model systems. These models help determine whether a variant is loss-of-function, gain-of-function, or neutral, and can guide personalized medicine approaches.
Knock-in
Knock-in of human transporter genes or regulatory elements into mouse models (e.g., humanized URAT1) enables in vivo studies of human-specific pharmacology and genetics. Tagged knock-in (e.g., GFP-URAT1) allows real-time imaging of transporter localization and trafficking.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of urate transporters in cell lines (e.g., HEK293, MDCK) is used to study transport kinetics, substrate specificity, and drug interactions [2, 6]. Overexpression systems are particularly useful for high-throughput screening of uricosuric compounds.
How EDITGENE Supports urate transport Research
Researchers studying urate transport-related genes often need to determine whether a candidate gene is causally involved in urate homeostasis or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell and animal models, enabling rigorous functional validation of urate transporters and their variants.
Contact EDITGENE today to design your custom CRISPR model for urate transport research.
Frequently Asked Questions About urate transport
What is urate transport (GO:0015747)?
Urate transport is the biological process of moving urate (uric acid) across cell membranes or between cells via transporters or pores, as defined by the Gene Ontology.
What genes are involved in urate transport?
Key genes include SLC22A12 (URAT1), SLC2A9 (GLUT9), ABCG2, SLC22A6 (OAT1), SLC22A8 (OAT3), and several other SLC family transporters [1, 2, 6].
How does urate transport relate to gout?
Dysregulated urate transport leads to hyperuricemia, a major risk factor for gout. Variants in URAT1, GLUT9, and ABCG2 are associated with gout [1, 4].
What is the role of URAT1 in urate transport?
URAT1 (SLC22A12) is an apical transporter in the renal proximal tubule that reabsorbs urate from the tubular lumen, and it is a target of uricosuric drugs.
What is the difference between transcellular and paracellular urate transport?
Transcellular transport involves movement through cells via transporters, while paracellular transport occurs between cells through tight junctions.
Which tissues are most important for urate transport?
The kidney (proximal tubule) and intestine are the primary sites of urate transport, with the kidney playing a dominant role in excretion [1, 3].
How can I study urate transport in the lab?
Common methods include radiolabeled urate uptake assays in cell lines, knockout mouse models, and CRISPR screens to identify novel regulators [2, 6].
What are the clinical implications of urate transport research?
It informs the development of urate-lowering therapies (e.g., URAT1 inhibitors) and helps predict drug responses and disease risk [2, 4].
Are there genetic diseases caused by urate transport defects?
Yes, loss-of-function mutations in URAT1 cause renal hypouricemia, and variants in GLUT9 and ABCG2 are linked to hyperuricemia and gout [1, 2].
How does CRISPR help in studying urate transport?
CRISPR enables knockout, knock-in, and point mutation models to test the causal role of specific transporters and variants in urate homeostasis [1, 2].
Conclusion
Urate transport (GO:0015747) is a fundamental biological process that maintains urate homeostasis and whose dysfunction underlies hyperuricemia, gout, and related metabolic disorders. The identification of multiple transporters and their genetic variants has advanced our understanding of urate handling and opened new therapeutic avenues. Continued research using CRISPR-based models and advanced structural techniques will further elucidate the mechanisms and regulation of urate transport, paving the way for precision medicine in gout and beyond.
References
- 1. Halperin Kuhns VL et al.. 2021. Urate transport in health and disease.. Best Pract Res Clin Rheumatol 35(4):101717 PMID: 34690083
- 2. Dai Y et al.. 2024. Transport mechanism and structural pharmacology of human urate transporter URAT1.. Cell Res 34(11):776-787 PMID: 39245778
- 3. Mount DB et al.. 2006. Renal urate transport.. Rheum Dis Clin North Am 32(2):313-31, vi PMID: 16716882
- 4. So A et al.. 2010. Uric acid transport and disease.. J Clin Invest 120(6):1791-9 PMID: 20516647
- 5. Kimura T et al.. 2019. Urate Transport via Paracellular Route across Epithelial Cells.. Biol Pharm Bull 42(1):43-49 PMID: 30606989
- 6. Anzai N et al.. 2007. New insights into renal transport of urate.. Curr Opin Rheumatol 19(2):151-7 PMID: 17278930
- 7. Dantzler WH. 1996. Comparative aspects of renal urate transport.. Kidney Int 49(6):1549-51 PMID: 8743452
- 8. Kahn AM et al.. 1985. Urate transport in the proximal tubule: in vivo and vesicle studies.. Am J Physiol 249(6 Pt 2):F789-98 PMID: 3000189
